Maxim Group initiated coverage on shares of GW Pharmaceuticals PLC- (NASDAQ:GWPH) in a research note published on Thursday, April 20th. The firm issued a buy rating and a $135.00 target price on the biopharmaceutical company’s stock.
“Epilepsy remains a challenging indication to treat, with over a third of patients (750k patients in the U.S.) who are inadequately controlled despite several antiepileptic drugs (market of $5B) taken concurrently. GW’s lead product, Epidiolex, an orphan drug designated oral CBD (cannabidiol), showed positive results in three P3 trials for Dravet (DS) and Lennox-Gastaut syndromes (LGS).”,” the firm’s analyst commented.
Several other brokerages have also recently issued reports on GWPH. Piper Jaffray Companies set a $147.00 target price on GW Pharmaceuticals PLC- and gave the company a buy rating in a report on Tuesday, February 7th. Goldman Sachs Group Inc reiterated a buy rating and set a $185.00 price